CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
接受 CAR-T 细胞治疗的大 B 细胞淋巴瘤患者桥接治疗后氟脱氧葡萄糖正电子发射断层扫描 delta 影像组学的预后意义
英文原题：Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy.
查看英文原题
Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
研究概要
bRT 使 MTV、SUVmax、SUVmean 和 TLG 显著降低。
中文摘要
材料与方法
回顾接受 bRT 后 CAR-T 细胞治疗的 LBCL 患者。提取 bRT 前以及 bRT 完成至 CAR-T 输注期间进行的 18F-氟脱氧葡萄糖 PET 扫描中的代谢肿瘤体积（MTV）、最大标准摄取值（SUVmax）、平均 SUV（SUVmean）和总病灶糖酵解（TLG）。据此计算各指标变化的 delta 放射组学参数，并分析其与肿瘤学结局（无进展生存期 [PFS]、无远处进展生存期 [FFDP] 和局部控制 [LC]）的关联。
结果
23 例 LBCL 患者共接受 33 个病灶部位照射，其中 10 例所有代谢活跃疾病均得到治疗。bRT 后，包括未照射部位在内的总体指标中位降幅为：MTV 22.2 cc（63.1%）、SUVmax 8.9（36.8%）、SUVmean 3.4（31.1%）、TLG 297.9 cc（75.8%）。照射部位的 MTV、SUVmax、SUVmean 和 TLG 中位降幅分别为 15.6 cc（91.1%）、17.0（74.6%）、6.8（55.3%）和 157.0 cc（94.6%）。中位随访 15.2 个月。SUVmax 至少下降 54% 与 PFS 改善（24 个月 PFS：83.3% 对 28.1%；p = 0.037）和 FFDP 改善（24 个月 FFDP：100% 对 62.4%；p < 0.001）相关。MTV 至少下降 90% 与 FFDP 改善相关（24 个月 FFDP：100% 对 62.4%；p < 0.001）。SUVmax 至少下降 71% 的照射部位局部控制更好（24 个月 LC：100% 对 72.7%；p < 0.001）。MTV 至少下降 90%（100% 对 53.3%；p = 0.038）和 TLG 至少下降 95%（100% 对 56.3%；p = 0.067）与完全缓解率提高相关。
结论
bRT 可显著降低 MTV、SUVmax、SUVmean 和 TLG。这些指标的相对降幅与 CAR-T 细胞输注后的结局改善相关。未来应由前瞻性队列验证 bRT 后中期 PET 在量化疾病负荷变化及相关预后方面的价值。
展开英文摘要原文
RESULTS
Thirty-three sites across 23 patients with LBCL were irradiated. All metabolically active disease was treated in 10 patients. Following bRT, median overall decreases (including unirradiated sites) in MTV, SUV max , SUV mean , and TLG were 22.2 cc (63.1%), 8.9 (36.8%), 3.4 (31.1%), and 297.9 cc (75.8%), respectively. Median decreases in MTV, SUV max , SUV mean , and TLG in irradiated sites were 15.6 cc (91.1%), 17.0 (74.6%), 6.8 (55.3%), and 157.0 cc (94.6%), respectively. Median follow-up was 15.2 months. A decrease in SUV max of at least 54% was associated with improved PFS (24-month PFS: 83.3% vs. 28.1%; p = 0.037) and FFDP (24-month FFDP: 100% vs. 62.4%; p < 0.001). A decrease in MTV of at least 90% was associated with improved FFDP (24-month FFDP: 100% vs. 62.4%; p < 0.001). LC was improved in sites with decreases in SUV max of at least 71% (24-month LC: 100% vs. 72.7%; p < 0.001). Decreases of MTV by at least 90% (100% vs. 53.3%; p = 0.038) and TLG by at least 95% (100% vs. 56.3%; p = 0.067) were associated with an improved complete response rate.
CONCLUSION
bRT led to substantial reductions in MTV, SUV max , SUV mean , and TLG. The relative extent of these decreases correlated with improved outcomes after CAR T-cell infusion. Prospective cohorts should validate the value of interim PET following bRT for quantifying changes in disease burden and associated prognosis.
论文信息
- 作者
- Ladbury C、Hao C、Watkins WT、Sampath S、Wong J、Amini A、Sokolov K、Yeh J
- 单位
- Department of Radiation Oncology, City of Hope National Medical Center, Duarte, CA, United States.United States
- 期刊
- Frontiers in immunology2024
- 原文标识
- PubMed 39411711 · DOI 10.3389/fimmu.2024.1419788
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →